My Compounding Pharmacy Debuts New Line of Customizable Medications
MELBOURNE, AUSTRALIA / ACCESS Newswire Australia's My Compounding Pharmacy has elevated the field of personalized medicine with the launch of an innovative range of products designed to cater to the unique healthcare needs of its customers. By offering a variety of compounded medications that include Low Dose Naltrexone Capsules, Ketoprofen and Lignocaine Cream, Amitriptyline Cream, Mi-Gel, Organogel, Gabapentin, Capsaicin, Clonidine Cream, Ketoprofen Capsules, and Magnesium Glycinate, My Compounding Pharmacy continues to reinforce its reputation as a leader in tailored pharmaceutical solutions.
Traditionally, pharmacies rely on pre-manufactured medications, leaving little flexibility for individuals who may have unique sensitivities or require specific formulations. My Compounding Pharmacy breaks this mold by creating medications from scratch, tailored to meet precise patient requirements. This personalized approach is particularly beneficial for those who struggle with off-the-shelf medications due to dosage limitations, delivery methods, or allergens commonly found in standard formulas.
The newly introduced products exemplify My Compounding Pharmacy 's dedication to pushing boundaries in the pharmaceutical space. For instance, Low Dose Naltrexone Capsules offer a tailored treatment option with potential applications in managing chronic conditions, while Ketoprofen and Lignocaine Cream provide an effective topical pain management solution for individuals seeking alternatives to oral medications. Amitriptyline Cream and Gabapentin, on the other hand, underscore their commitment to addressing nerve pain and related conditions with customized dosage forms.
Mi-Gel and Organogel represent the pharmacy's ability to innovate beyond traditional methods, providing patients with novel drug delivery systems that improve ease of application and effectiveness. Similarly, Capsaicin and Clonidine Creams offer cutting-edge options for pain management by targeting specific issues directly through the skin. Magnesium Glycinate provides an alternative supplement for individuals requiring magnesium supplementation without the gastrointestinal discomfort often associated with mass-market options.
The company's ability to deliver such a diverse and customized inventory is anchored by its state-of-the-art facilities and highly skilled team. My Compounding Pharmacy adheres strictly to the guidelines set by the Pharmacy Board of Australia and the Therapeutic Goods Administration (TGA), ensuring every product meets the highest standards of safety and efficacy. Their team of pharmacists has 85 years of combined expertise, reflecting a commitment to excellence that is deeply embedded in their operations.
With one of the most extensive inventories in the country, My Compounding Pharmacy ensures timely access to critical medications, whether through same-day pickup, next-day courier service, or express post to customers in Sydney and beyond. They also offer a modern solution for local delivery via the Chemist2U pharmacy delivery app, aiming to eliminate delays in access to essential treatments.
The pharmacy doesn't just stop at filling individual prescriptions-it reimagines what it means to deliver healthcare solutions by providing options for those who might otherwise be left without alternatives. Whether it's a child who struggles to swallow pills, a senior who requires a lower dosage, or an allergy sufferer seeking relief without unwanted additives, My Compounding designs solutions that directly enhance patient quality of life.
Patients who require access to discontinued medications or need combinations of active ingredients in a single dosage form benefit greatly from their services. For children and pets, they've introduced options for improving taste or creating appetizing, user-friendly compounds. These efforts demystify the process of taking medication, ensuring better adherence to prescribed treatments.
By continuously evolving its offerings, My Compounding Pharmacy not only adapts to modern healthcare needs but sets a benchmark for excellence, care, and innovation in an increasingly complex medical landscape. Their vision has reshaped expectations for pharmacies, proving that individualized solutions are not only achievable but necessary for better health outcomes.
The addition of this new product range further underscores the company's dedication to personalized care. Whether you're looking for allergen-free treatments, tailored dosages, or innovative delivery methods, My Compounding is standing by to provide life-enhancing solutions that put individual needs at the forefront of modern medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 hours ago
- Associated Press
NBJ Summit 2025 Brings Industry Visionaries Together to Shape Nutrition's Future
RANCHO PALOS VERDES, CA / ACCESS Newswire / June 11, 2025 / The nutrition and dietary supplements industry's premier gathering, NBJ Summit 2025, will convene top executives and thought leaders at the Terranea Resort in Rancho Palos Verdes, Calif. from July 28-31, 2025. With the central theme of 'Nutrition Industry Transformation,' this year's summit addresses the seismic shifts reshaping the nearly $70 billion dollar industry landscape. This year's event comes at a critical time, promising to mobilize leaders around topics presenting challenges and opportunities for consumers and the industry. The NBJ Summit, hosted by New Hope Network, offers an unparalleled opportunity for industry leaders to engage in four days of intensive education, strategic networking and forward-thinking discussions about the future of nutrition and dietary supplements. The State of the Industry presentation featuring Nutrition Business Journal (NBJ) industry data will set the stage for the week. 'In an era of exponential change, this year's agenda directly confronts the forces reshaping our industry and provides executives with actionable strategies to thrive amid disruption,' says Jessica Rubino, VP of Content and Summits, who serves as NBJ Summit Co Chair, along with Bill Giebler, Nutrition Business Journal Content & Insights Director, and Tom Aarts, NBJ Summit Founder 'We're bringing together the most innovative leaders to navigate this new landscape where healthcare and supplement industry convergence, digital transformation, regulatory shifts and personalized nutrition are fundamentally reshaping our industry.' The 2025 agenda addresses four critical transformation areas: A disruptive perspective on healthcare economics will be delivered by Calley Means, Co-Founder of Truemed, featuring compelling data demonstrating nutrition's critical role in addressing systemic health challenges. Complementing this vision, Dr. Lise Alschuler will reveal clinical pathways reshaping patient care, while James LaValle demonstrates how scientific insights create market advantages for forward-thinking companies. Dr. William Davis rounds out this powerful segment by sharing an influential vision for the nutrition-centered health transformation changing consumer expectations. Business transformation renders yesterday's business models obsolete, and the Summit brings together leading experts in technology and innovation. AI specialists Mitch Mitchum, HIVE Interactive; Afif Ghannoum, CPG Radar; and Akash Shah, IngredientAI will reveal strategic applications of artificial intelligence that are driving growth across the nutrition value chain. Plus, innovation catalyst Diana Kander delivers a highly anticipated keynote on curiosity-driven innovation, offering attendees a rare opportunity to learn from one of today's most sought-after business advisors whose insights have transformed companies across multiple industries. The regulatory landscape continues to evolve at an unprecedented pace, creating both challenges and opportunities for nutrition businesses. Industry advocates Douglas 'Duffy' MacKay, ND; Miriam Guggenheim of Covington & Burling LLP; and Steve Mister, Esq., President & CEO of the Council for Responsible Nutrition, will provide essential insights on compliance challenges and policy shifts reshaping the competitive landscape. MacKay and Mister's collective expertise offers attendees a comprehensive understanding of how to navigate complex regulatory environments while maintaining competitive advantage. As the future of nutrition and retail are increasingly individualized, the Summit aims to showcase the pioneers leading this revolution. Biohacking phenomenon Ben Greenfield will share cutting-edge optimization techniques that are redefining consumer expectations around personalized nutrition. Renowned longevity researcher Brian Kennedy will reveal breakthroughs in cognitive enhancement, creating entirely new market categories. Retail experts from Amazon, TikTok and more will also share invaluable insights on emerging trends shaping the future of supplement retail in a personalized and omnichannel world, offering attendees practical strategies for adapting to rapidly evolving consumer behaviors and expectations. The Summit culminates in an Executive Wellness Experience featuring a meticulously crafted Wellness Lunch, intimate networking with industry leaders and hands-on experiences with emerging biohacking modalities, nourishing wellness treatments and functional libations. The NBJ Summit welcomes top nutrition industry CEOs and executives to this exclusive in-person event. For registration information and the complete agenda, visit NBJ Summit offers virtual registration to all who are interested. Virtual participants will have access to all education sessions, networking opportunities and will be able to connect with both in-person and virtual attendees on the virtual event platform. For more information, please visit About Nutrition Business Journal Nutrition Business Journal guides decision makers in the nutrition, health, and wellness space in developing their strategy, understanding trends, realizing opportunity, and analyzing potential risks. NBJ's market research reports provide business intelligence and thought leadership to all levels of the nutrition industry. Each report is exhaustively researched by our staff of industry experts and presents an analysis of markets, trends, competition, and strategy in the U.S. and global nutrition industry. Learn more at About Informa Markets Informa Markets, a subsidiary of Informa plc (LON:INF), creates platforms for industries and specialist markets to trade, innovate and grow. With a global reach and diverse portfolio of verticals, including Pharmaceuticals, Food, Medical Technology and Infrastructure, Informa Markets connects buyers and sellers worldwide through face-to-face exhibitions, targeted digital services and actionable data solutions. For more information, visit Media Contact [email protected] SOURCE: New Hope Network press release
Indianapolis Star
14 hours ago
- Indianapolis Star
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar's field study of Canalevia-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally. 'We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,' said Lisa Conte, Jaguar's Founder and CEO. 'We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.' 'Jaguar's canine-focused business development efforts align with our ongoing business development efforts on the 'human' side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.' The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group. As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA's Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs. Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs. Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy. About Conditional Approval and Full Approval Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the 'substantial evidence' standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving 'substantial evidence of effectiveness' for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer. 1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S. Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment, 2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs. About Canalevia ® -CA1 Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a 'small number' threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use. About Crofelemer Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities. Important Safety Information About Canalevia ® -CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar's expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar's expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar's expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 'Cancer in Pets.' American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Indianapolis Star
15 hours ago
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson's disease. Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies. These new results build on earlier in vitro studies that confirmed Telomir-1's high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1's copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson's disease. In the ATP7B C271X -/- zebrafish model, which mimics human Wilson's disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features: Key Findings from the Study: Up to a 4- to 5-fold reduction in episodic tremor events Normalization of swim distance, swim velocity, and exploratory behavior Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles) Approximately 50% reduction in copper accumulation in dry liver tissue Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels Normalization of ALT, AST, and bilirubin-three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage Improved survival under high copper exposure conditions 'We've now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson's disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,' said Erez Aminov, Chairman and CEO of Telomir. 'In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson's disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.' 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease,' added Dr. Angel, Chief Scientific Advisor. 'Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.' Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
